A malarial drug is showing promise in stopping breast cancer before it starts, Mason researchers are discovering during a clinical trial. "The bold long-term goal is a short-term oral treatment that prevents breast cancer by killing the precursor cells that initiate breast cancer," says Lance Liotta, co-director of Mason's Center for Applied Proteomics and Molecular Medicine (CAPMM)...
More...
Linear Mode
